Medicines affordability in the US

Some people with diabetes in the US are increasingly finding it hard to pay for their medicines, especially those uninsured and in high-deductible healthcare plans. This is not acceptable.

In line with our social responsibility, we have launched initiatives and programmes offering people living with diabetes in the US insulin affordability options. These include:

  • Providing a , which in 2018 provided free insulin to nearly 50,000 people with diabetes. Through the programme, an individual with an annual income up to 49,960 US dollars, and a family of four with a combined annual income up to 103,000 US dollars, may qualify for free Novo Nordisk medicines - including all of our insulin products.
  • Making low-cost human insulin available at . This offering has been in place for almost two decades and has recently been made available in other national pharmacy chains through programmes with CVS and ESI. Around 500,000 Americans are using our human insulin through these partnerships. 
  • Through our  offering, all eligible patients can purchase up to three vials or two packs of FlexPen®/FlexTouch®/Penfill® pens of any combination of insulins from Novo Nordisk Inc. for $99 with a prescription.
  • Offering to help defray out-of-pocket costs for commercially-insured patients.
  • An option available for people facing an acute need when more time is needed to identify a long-term sustainable solution.
  • Making of two of our modern insulins from new Novo Nordisk A/S US company, Novo Nordisk Pharma, Inc., available at pharmacies within 1-3 business days at 50 percent off the list price.

The complexity of the US healthcare system means that arriving at solutions that ensure affordable access to medicines for all is not straightforward. However, we believe that with collaboration across all parties in the system, sustainable solutions can be achieved.

We want to be part of a solution and we are actively working with stakeholders across the US healthcare system to find ways that help reduce the burden on patients both in the short-term and for longer-term reform.


Our position on pricing and affordability in the US


Our collaborations towards affordable medicines for americans

Our collaborations towards affordable medicines for Americans



Our patient assistance programme in the U.S. (PAP)


河北11选5 北京快3 新疆喜乐彩app 河南快3 福建快3 甘肃快3 北京快3 极速快三 一品彩票开户 贵州快3